Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders.

Ren P, Zhang Y, Huang Y, Yang Y, Jiang M.

Clin Med Insights Oncol. 2015 Apr 27;9:43-9. doi: 10.4137/CMO.s23527. eCollection 2015. Review.

2.

Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis.

Li R, Dong X, Ma C, Liu L.

Theor Biol Med Model. 2014 Aug 23;11:37. doi: 10.1186/1742-4682-11-37.

3.

Limited Applicability of GW9662 to Elucidate PPARγ-Mediated Fatty Acid Effects in Primary Human T-Helper Cells.

Jaudszus A, Lorkowski S, Gruen M, Roth A, Jahreis G.

Int J Inflam. 2014;2014:149628. doi: 10.1155/2014/149628. Epub 2014 Jun 25.

4.

T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe.

An Z, Muthusami S, Yu JR, Park WY.

Reprod Sci. 2014 Nov;21(11):1352-61. doi: 10.1177/1933719114525265. Epub 2014 Mar 18.

5.

PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells.

Wojtowicz AK, Szychowski KA, Kajta M.

Neurotox Res. 2014 Apr;25(3):311-22. doi: 10.1007/s12640-013-9434-z. Epub 2013 Oct 17.

6.

Effect of angiotensin II type 2 receptor-interacting protein on adipose tissue function via modulation of macrophage polarization.

Jing F, Mogi M, Min LJ, Ohshima K, Nakaoka H, Tsukuda K, Wang X, Iwanami J, Horiuchi M.

PLoS One. 2013;8(4):e60067. doi: 10.1371/journal.pone.0060067. Epub 2013 Apr 2.

7.

Cytotoxicity of 15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma.

Fujita M, Tohji C, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N.

Int J Med Sci. 2012;9(7):555-66. Epub 2012 Sep 4.

8.
9.

Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8.

Aizawa J, Sakayama K, Kamei S, Kidani T, Yamamoto H, Norimatsu Y, Masuno H.

BMC Cancer. 2010 Feb 22;10:51. doi: 10.1186/1471-2407-10-51.

10.

Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells.

Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, Sun Z.

Reprod Biol Endocrinol. 2009 Dec 9;7:147. doi: 10.1186/1477-7827-7-147.

11.

Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions.

Van Landeghem L, Mahé MM, Teusan R, Léger J, Guisle I, Houlgatte R, Neunlist M.

BMC Genomics. 2009 Nov 2;10:507. doi: 10.1186/1471-2164-10-507.

12.

The prince and the pauper. A tale of anticancer targeted agents.

Dueñas-González A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M.

Mol Cancer. 2008 Oct 23;7:82. doi: 10.1186/1476-4598-7-82. Review.

13.
14.

Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease.

Peters JM, Hollingshead HE, Gonzalez FJ.

Clin Sci (Lond). 2008 Aug;115(4):107-27. doi: 10.1042/CS20080022. Review.

15.

PPARgamma and Apoptosis in Cancer.

Elrod HA, Sun SY.

PPAR Res. 2008;2008:704165. doi: 10.1155/2008/704165.

16.

PPARgamma Inhibitors as Novel Tubulin-Targeting Agents.

Schaefer KL.

PPAR Res. 2008;2008:785405. doi: 10.1155/2008/785405.

17.

Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.

Magenta G, Borenstein X, Rolando R, Jasnis MA.

BMC Cancer. 2008 Feb 8;8:47. doi: 10.1186/1471-2407-8-47.

18.

Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.

Brown JS Jr.

Schizophr Bull. 2009 Jan;35(1):256-78. doi: 10.1093/schbul/sbm147. Epub 2008 Jan 31. Review.

Items per page

Supplemental Content

Write to the Help Desk